LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Home・Elenco Azioni・Roivant Sciences Ltd

Roivant Sciences Ltd

Chiusa

SettoreSettore sanitario

29.13 -2.9

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

29.04

Massimo

29.58

Metriche Chiave
By Trading Economics
Entrata	669M 356M
Vendite	521K 2.5M
Margine di Profitto	14,116.825
Dipendenti	721
EBITDA	-65M -354M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+26.14% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	1.3B 21B
Apertura precedente	32.03
Chiusura precedente	29.13

Notizie sul Sentiment di mercato

By Acuity

24%

76%

44 / 344 Classifica in Healthcare

Roivant Sciences Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 giu 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 giu 2026, 23:38 UTC

Acquisizioni, Fusioni, Takeovers

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 giu 2026, 23:37 UTC

Discorsi di Mercato

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 giu 2026, 23:01 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

1 giu 2026, 23:01 UTC

Discorsi di Mercato

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 giu 2026, 22:08 UTC

Acquisizioni, Fusioni, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 giu 2026, 22:01 UTC

Acquisizioni, Fusioni, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 giu 2026, 22:01 UTC

Acquisizioni, Fusioni, Takeovers

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 giu 2026, 21:55 UTC

Acquisizioni, Fusioni, Takeovers

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 giu 2026, 21:53 UTC

Discorsi di Mercato

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 giu 2026, 21:22 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 giu 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

1 giu 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

1 giu 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

1 giu 2026, 20:46 UTC

Acquisizioni, Fusioni, Takeovers

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 giu 2026, 20:22 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 giu 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 giu 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Declares $11 Special Div

1 giu 2026, 20:20 UTC

Acquisizioni, Fusioni, Takeovers

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 giu 2026, 19:40 UTC

Discorsi di Mercato

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 giu 2026, 19:28 UTC

Discorsi di Mercato

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 giu 2026, 19:01 UTC

Discorsi di Mercato

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 giu 2026, 18:58 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 giu 2026, 18:54 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 giu 2026, 18:33 UTC

Discorsi di Mercato

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 giu 2026, 18:32 UTC

Discorsi di Mercato

Precious Metals Fall to Start June -- Market Talk

1 giu 2026, 18:00 UTC

Acquisizioni, Fusioni, Takeovers

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 giu 2026, 17:18 UTC

Discorsi di Mercato

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 giu 2026, 17:18 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

1 giu 2026, 17:10 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Confronto tra pari

Modifica del prezzo

Roivant Sciences Ltd Previsione

Obiettivo di Prezzo

By TipRanks

26.14% in crescita

Previsioni per 12 mesi

Media 37.83 USD 26.14%

Alto 42 USD

Basso 31.5 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

44 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.